We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRRO icon
251
CALL
Korro Bio
KRRO
$150M
– –
-4,000
Closed -$1.9M
KURA icon
252
CALL
Kura Oncology
KURA
$800M
– –
-140,000
Closed -$3.96M
KURA icon
253
Kura Oncology
KURA
$800M
– –
-15,603
Closed -$441K
LEGN icon
254
PUT
Legend Biotech
LEGN
$3.59B
– –
-1,500
Closed -$44K
MCRB icon
255
Seres Therapeutics
MCRB
$46.8M
– –
-17,500
Closed -$7.38M
MRNA icon
256
CALL
Moderna
MRNA
$21.8B
– –
-100,000
Closed -$13.1M
MRNA icon
257
PUT
Moderna
MRNA
$21.8B
– –
-600,000
Closed -$78.6M
MRSN
258
CALL
DELISTED
Mersana Therapeutics
MRSN
– –
-8,000
Closed -$3.24M
MSOS icon
259
CALL
AdvisorShares Pure US Cannabis ETF
MSOS
$858M
– –
-150,000
Closed -$6.36M
NUVB icon
260
Nuvation Bio
NUVB
$2.2B
– –
-250,000
Closed -$2.61M
NVAX icon
261
CALL
Novavax
NVAX
$1.2B
– –
-70,000
Closed -$12.7M
NVAX icon
262
PUT
Novavax
NVAX
$1.2B
– –
-195,700
Closed -$35.5M
PDSB icon
263
PDS Biotechnology
PDSB
$38.4M
– –
-383,373
Closed -$1.75M
PRTA icon
264
Prothena Corp
PRTA
$425M
– –
-437,430
Closed -$11M
QQQ icon
265
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-200,000
Closed -$63.8M
RARE icon
266
PUT
Ultragenyx Pharmaceutical
RARE
$2.45B
– –
-18,400
Closed -$2.09M
RAPT
267
CALL
DELISTED
RAPT Therapeutics
RAPT
– –
-31,250
Closed -$5.55M
RCKT icon
268
Rocket Pharmaceuticals
RCKT
$340M
– –
-1,400
Closed -$61K
RVMD icon
269
CALL
Revolution Medicines
RVMD
$39.9B
– –
-150,000
Closed -$6.88M
SAGE
270
DELISTED
Sage Therapeutics
SAGE
– –
-91,151
Closed -$6.44M
SDGR icon
271
PUT
Schrodinger
SDGR
$1.13B
– –
-100,000
Closed -$7.63M
SLS icon
272
SELLAS Life Sciences
SLS
$1.97B
– –
-48,053
Closed -$410K
SMH icon
273
PUT
VanEck Semiconductor ETF
SMH
$65.2B
– –
-200,000
Closed -$24.4M
SNDX icon
274
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-40,913
Closed -$914K
SOXX icon
275
PUT
iShares Semiconductor ETF
SOXX
$41.7B
– –
-300,000
Closed -$42.4M
9 10
11
12 13

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.